Core Insights - Dyadic Applied BioSolutions and BRIG BIO have signed a Development and Commercialization Agreement to jointly develop and commercialize recombinant bovine alpha-lactalbumin [1][2] Partnership Overview - The partnership aims to leverage Dyadic's innovation capabilities and BRIG BIO's expertise in dairy and medical nutrition to produce scalable, cost-effective animal-free alpha-lactalbumin for various nutrition markets [2][6] - BRIG BIO will fully fund the development program and obtain a global commercial license for Dyadic's production strains, while Dyadic will receive milestone payments and revenue participation from commercial sales [3] Market Potential - The global market for alpha-lactalbumin is projected to grow from approximately USD 760 million in 2025 to over USD 1.6 billion by 2035, driven by demand in infant formula and medical nutrition [4][5] - The shift towards high-purity, functional proteins and the advantages of precision-fermented alpha-lactalbumin over traditional dairy sources are expected to support long-term adoption by global nutrition brands [5] Leadership Commentary - Dyadic's President & COO highlighted that the agreement positions the company to benefit from milestone and royalty revenue, as well as co-marketing rights, emphasizing the alignment of both companies' strengths [7] - BRIG BIO's CEO noted that the collaboration will enhance their ability to deliver high-quality, precision-fermented dairy proteins, addressing global food uncertainty [8] Company Profiles - Dyadic Applied BioSolutions specializes in producing recombinant proteins for life sciences, food and nutrition, and bio-industrial markets, utilizing its proprietary microbial platforms [9] - BRIG BIO focuses on developing scalable, functional recombinant dairy proteins, emphasizing precision fermentation to secure high-performance nutritional products [10]